This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Neuroendocrine Tumors or Pancreatic Neoplasms
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.

Provided treatments

  • Drug: TH-302 + Sunitinib
Tris trial is registered with FDA with number: NCT02402062. The sponsor of the trial is Grupo Espanol de Tumores Neuroendocrinos and it is looking for 16 volunteers for the current phase.
Official trial title:
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)